1. Market Research
  2. > Pharmaceutical Market Trends
  3. > GMR Data - The Indian Pharmaceutical Market - Leading Domestic Companies 2015

This report discusses the Indian pharmaceutical industry in depth, with specific focus on the ten leading domestic India pharmaceutical companies; their key financials since FY2011; their key global markets; their Merger, Acquisition and Joint Venture activity; their Research & Development spending; as well as Strength, Weakness, Opportunity and Threats that each individual company faces. This report also offers a snapshot of the key financials in the India pharmaceutical sector; import / export values, and where the India based pharmaceutical companies are generating their revenue globally. The report concludes with interviews with directors of Ipca Laboratories, Cadila Healthcare and Cipla.

The Indian Pharmaceutical Market - Leading Domestic Companies 2015 also highlights what drives, or restrains, the market for these leading companies;

Key Drivers

US Generics Market
JV, Acquisitions & Mergers
Patent Cliff
Increased Domestic Health Spending
Geographic Expansion into Semi-Regulated and Emerging Pharma Markets
Economies in Drug Production/Manufacture
Governmental Support

Key Restraints

Industry Inefficiencies
Regulatory Non-Compliance
Price Ceilings
Intellectual Property Rights / Compulsory Licence
Inadequate Health Insurance, India


The US generics market has been a massive growth driver for the India pharmaceutical market, with many leading companies in GMR Data’s list generating over 50% of their annual revenues from the US generics market. However with access to the US market comes increased scrutiny from the US FDA; nearly all the companies in the top ten have faced warnings from the FDA; ranging from minor procedural infractions to complete manufacturing shutdown.

The report contains over 130 tables & figures across 152 pages and concludes with 3 exclusive interviews with managing directors of 3 leading Indian pharmaceutical companies;
Cipla
Cadila Healthcare
IPCA Laboratories

Table Of Contents

GMR Data - The Indian Pharmaceutical Market - Leading Domestic Companies 2015
1 Executive Summary

1.1 Executive Summary
1.2 Research and Analysis Methods
1.3 Drivers and Restraints
1.3.1 Drivers
1.3.1.1 US Generics Market
1.3.1.2 JV, Acquisitions and Mergers
1.3.1.3 Patent Cliff
1.3.1.4 Increased Domestic Health Spending
1.3.1.5 Geographic Expansion into Semi-Regulated and Emerging Pharma Markets
1.3.1.6 Economies in Drug Production/Manufacture
1.3.1.7 Governmental Support
1.3.2 Restraints
1.3.2.1 Industry Inefficiencies and Regulatory Non-Compliance
1.3.2.2 Price Ceilings
1.3.2.3 Intellectual Property Rights / Compulsory Licence
1.3.2.4 Inadequate Health Insurance, India

2 Indian Pharmaceutical Market Overview

2.1 Evolution of the India Pharmaceutical Sector
2.1.1 Key Reforms/Regulations
2.1.2 Customers/End-Users
2.1.3 Pricing/Reimbursement
2.1.4 Competitive Landscape

3 India Pharmaceutical Market Revenue

3.1 Pharmaceutical Market Revenue - Domestic
3.2 Pharmaceutical Market Revenue - Export
3.3 Domestic Pharmaceutical Drugs Market Share

4 - The 10 Leading Indian Pharmaceutical Companies 2015

4.0.1 The Top Ten India Pharmaceutical Companies FY2015, by Revenue
4.0.2 The Top Ten Domestic and Foreign Revenue Generators FY2015
4.0.3 The Top Ten RandD Spending FY2015

4.1 Sun Pharmaceutical Industries Ltd
4.1.1 Sun Pharma Company Profile
4.1.2 Sun Pharma Financial Analysis
4.1.3 Sun Pharma SWOT Analysis
4.1.3.1 Strengths
4.1.3.1.1 Robust RandD Spending
4.1.3.1.2 Strong Drugs Pipeline
4.1.3.1.3 Strong Position in Key Markets
4.1.3.2 Weaknesses
4.1.3.2.1 Export Dependency
4.1.3.3 Opportunities
4.1.3.3.1 Capitalisation on the Ranbaxy Acquisition
4.1.3.3.2 Further Acquisition
4.1.3.4 Threats
4.1.3.4.1 FDA warnings
4.1.3.4.2 Ranbaxy Merger Issues

4.2 Dr Reddy's Laboratories Ltd.
4.2.1 Dr Reddy's Company Profile
4.2.2 Dr Reddy's Financial Analysis
4.2.3 Dr Reddy SWOT Analysis
4.2.3.1 Strengths
4.2.3.1.1 Global Presence through Strategic Acquisitions and Partnerships
4.2.3.1.2 Generic Sales in Key Geographies
4.2.3.1.3 Strong Operational Infrastructure and Robust Base for Research
4.2.3.2 Weaknesses
4.2.3.2.1 Increased RandD spending to put Pressures on Margins
4.2.3.3 Opportunities
4.2.3.3.1 Growth in US Generic Market
4.2.3.3.2 Biosimilars Market Opportunity
4.2.3.4 Threats
4.2.3.4.1 Economic / Political Uncertainties in Some Markets
4.2.3.4.2 Manufacturing Issues Leading to FDA Scrutiny / Drug Recalls

4.3 Lupin Ltd
4.3.1 Lupin Company Profile
4.3.2 Lupin Financial Analysis
4.3.3 Lupin SWOT Analysis
4.3.3.1 Strengths
4.3.3.1.1 Strong US Presence
4.3.3.1.2 Diverse ROW Sales Revenue
4.3.3.1.3 Acquisitions / JVs
4.3.3.2 Weaknesses
4.3.3.2.1 Net Exporter
4.3.3.3 Opportunities
4.3.3.3.1 Japan
4.3.3.3.2 Anti-TB Market
4.3.3.4 Threats
4.3.3.4.1 Consolidation in the US Pharmaceutical Industry
4.4 Cipla Ltd
4.4.1 Cipla Company Profile
4.4.2 Cipla Financial Analysis
4.4.3.1 Strengths
4.4.3.1.1 Global Presence
4.4.3.1.2 Numerous Global JVs/Acquisitions
4.4.3.1.3 RandD Focus
4.4.3.2 Weaknesses
4.4.3.2.1 Robust Competition
4.4.3.3 Opportunities
4.4.3.3.1 Focus on Key Markets
4.4.3.3.2 Successful Launch of Late Stage Pipeline
4.4.3.3.3 Investment in MMV
4.4.3.4 Threats
4.4.3.4.1 FDA Approval
4.4.3.4.2 Domestic Pricing Regulations


4.5 Zydus Cadila Healthcare Ltd
4.5.1 Cadila Company Profile
4.5.2 Cadila Financial Analysis
4.5.3 Cadila SWOT Analysis
4.5.3.1 Strengths
4.5.3.1.1 Drug Approval History
4.5.3.1.2 Solid Platforms in Key Markets
4.5.3.1.3 JVs, Alliances and Subsidiaries
4.5.3.2 Weaknesses
4.5.3.2.1 Delays in Approval
4.5.3.2.2 Price Controls
4.5.3.3 Opportunities
4.5.3.3.1 RandD Strength
4.5.3.3.2 Opportunities to Strengthen their Global Markets
4.5.3.4 Threats
4.5.3.4.1 Further FDA Warnings

4.6 Aurobindo Pharma Limited
4.6.1 Aurobindo Company Profile
4.6.2 Aurobindo Financial Analysis
4.6.3 Aurobindo SWOT Analysis
4.6.3.1 Strengths
4.6.3.1.1 Acquisitions / JVs
4.6.3.1.2 Sales from both Domestic and Global Market
4.6.3.1.3 Strong in-house RandD Base
4.6.3.2 Weaknesses
4.6.3.2.1 Unscheduled Changes in Management
4.6.3.3 Opportunity
4.6.3.3.1 Strength of Approved Fillings, Internationally
4.6.3.3.2 Strong Pipeline
4.6.3.3.3 Geographical Growth
4.6.3.4 Threats
4.6.3.4.1 Competition
4.6.3.4.2 Regulatory and Compliance Risks
4.6.3.4.3 Pricing risks

4.7 Glenmark Pharmaceuticals Ltd.
4.7.1 Glenmark Company Profile
4.7.2 Glenmark Financial Analysis
4.7.3 Glenmark SWOT Analysis
4.7.3.1 Strengths
4.7.3.1.1 Strong RandD Base
4.7.3.1.2 Revenue from Multiple Markets
4.7.3.2 Weakness
4.7.3.2.1 Organic Growth
4.7.3.3 Opportunities
4.7.3.3.1 Continued Growth in Global Markets
4.7.3.4 Threats
4.7.3.4.1 Litigation


4.8 Jubilant Life Sciences
4.8.1 Jubilant Company Profile
4.8.2 Jubilant Financial Analysis
4.8.3.1 Strengths
4.8.3.1.1 Attracts Foreign Investment
4.8.3.1.2 Multiple Global Production Bases
4.8.3.2 Weaknesses
4.8.3.2.1 RandD Effectiveness
4.8.3.3 Opportunities
4.8.3.3.1 Expanding Global Drugs Pipeline
4.8.3.3.2 Geographical Expansion
4.8.3.3.3 Significant Subsidiaries / Collaborations
4.8.3.4 Threats
4.8.3.4.1 Rising Raw Material Prices


4.9 Torrent Pharmaceuticals Limited
4.9.1 Torrent Company Profile
4.9.2 Torrent Financial Analysis
4.9.3 Torrent SWOT Analysis
4.9.3.1 Strengths
4.9.3.1.1 Revenue Generated in Diverse Geographical Markets
4.9.3.1.2 Integration of Elder Pharma
4.9.3.2 Weaknesses
4.9.3.2.1 RandD Spending
4.9.3.3 Opportunities
4.9.3.3.1 Growth in Torrent's Global Markets
4.9.3.3.2 Global Drugs Pipeline
4.9.3.4 Threats
4.9.3.4.1 Drug Price Controls
4.9.3.4.2 Litigation

4.10 Wockhardt Limited
4.10.1 Wockhardt Company Profile
4.10.2 Wockhardt Financial Analysis
4.10.3 Wockhardt SWOT Analysis
4.10.3.1 Strengths
4.10.3.1.1 RandD Spending
4.10.3.1.2 Multiple Markets Generating Revenue
4.10.3.2 Weaknesses
4.10.3.2.1 Regulatory Warnings
4.10.3.2.2 US Sales Growth
4.10.3.3 Opportunity
4.10.3.3.1 Further MandA
4.10.3.4 Threat
4.10.3.4.1 Increased Regulatory Scrutiny

5 Expert Opinion

5.1 Cipla Ltd
5.2 Cadila Healthcare
5.3 IPCA Laboratories

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

  • $ 10995
  • Industry report
  • September 2016
  • by Global Data

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024 Summary Attention deficit hyperactivity disorder (ADHD) is characterized by excessive levels ...

Global Pharmaceutical Contract Manufacturing Organization (CMO) Market

Global Pharmaceutical Contract Manufacturing Organization (CMO) Market

  • $ 7000
  • Industry report
  • August 2016
  • by Frost & Sullivan

Emerging Business Models Drive Transformation The key objective of this research is to provide in-depth knowledge of the major global pharmaceutical CMO market segments—active pharmaceutical ingredients ...

Frontier Pharma: Asthma Therapeutics - Cytokine and Kinase Targeted Small Molecules and mAbs Increase Pipeline Diversity and Dominate First-in-Class Innovation

Frontier Pharma: Asthma Therapeutics - Cytokine and Kinase Targeted Small Molecules and mAbs Increase Pipeline Diversity and Dominate First-in-Class Innovation

  • $ 6995
  • Industry report
  • November 2016
  • by GBI Research

Frontier Pharma: Asthma Therapeutics - Cytokine and Kinase Targeted Small Molecules and mAbs Increase Pipeline Diversity and Dominate First-in-Class Innovation Summary Asthma is a chronic condition affecting ...


ref:plp2015

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.